NEW YORK (GenomeWeb News) — Lipomics today said it will provide its lipid metabolite services to Isis Pharmaceuticals.
Under the terms of the agreement, Lipomics will support Isis in its pre-clinical and clinical trials of lipid compounds that may be used to treat metabolic diseases.
Lipomics said it will hold exclusive rights to develop diagnostics that result from the research, while Isis will retain rights to therapeutics.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.